今年6月7日,渤健(Biogen)基于β-淀粉样蛋白假说而开发的第一款用于治疗AD的单克隆抗体药物Aduhelm历经波折,终获得美国FDA批准上市,是近20年来AD领域首款新疗法...查看全文
$Trident(TDAC)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001213900-21-034797 Act: 34 Size: 3 MB 网页链接
$Trident(TDAC)$ 425 Prospectuses and communications, business combinations Accession Number: 0001213900-21-034330 Act: 34 Size: 92 KB 网页链接
$Trident(TDAC)$ 8-K Current report, item 3.01 Accession Number: 0001213900-21-034262 Act: 34 Size: 263 KB 网页链接
$Trident(TDAC)$ 8-K Current report, item 4.02 Accession Number: 0001213900-21-033058 Act: 34 Size: 277 KB 网页链接
$Trident(TDAC)$ 425 Prospectuses and communications, business combinations Accession Number: 0001213900-21-032219 Act: 34 Size: 53 KB 网页链接
$Trident(TDAC)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001213900-21-032218 Act: 34 Size: 52 KB 网页链接
$Trident(TDAC)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001213900-21-031725 Act: 34 Size: 55 KB 网页链接
$Trident(TDAC)$ 425 Prospectuses and communications, business combinations Accession Number: 0001213900-21-031726 Act: 34 Size: 56 KB 网页链接
$Trident(TDAC)$ 425 Prospectuses and communications, business combinations Accession Number: 0001213900-21-030670 Act: 34 Size: 78 KB 网页链接
$Trident(TDAC)$ 8-K Current report, items 3.01 and 9.01 Accession Number: 0001213900-21-030544 Act: 34 Size: 278 KB 网页链接